clinical trial · NCT07429266
A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
Ono Pharmaceutical Co., Ltd.·phase3·not yet recruiting·n = 250
Polycythemia VeraSapablursenPlacebo
brief summary
The purpose of this study is to evaluate the efficacy and safety of sapablursen when added on to current standard of care (SOC) for Polycythemia Vera (PV) therapy. The study will be conducted in three sequential parts (Part 1a blinded treatment, Part 1b open-label treatment, \& Part 2 long-term extension). Participants may receive treatment for up to 156 weeks.
started
Jun 1, 2026
primary completion
Sep 1, 2028
completion
Jan 1, 2031
last updated
Feb 24, 2026
official title
A Phase 3 Randomized, Double-blind, Placebo-controlled Global Study of Sapablursen in Polycythemia Vera
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol